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Abstract
A simple, specific, accurate and precise reverse phase high performance liquid chromatography (RP-HPLC) method was developed for the 
estimation of valsartan in solid oral dosage form. The chromatographic separation of valsartan was achieved under the following conditions:  
mobile phase containing acetate buffer (pH4.6): acetonitrile: methanol (38:24:38 %, v/v); ODS C18 (250 mm × 4.6 mm, 5 ìm) analytical column 
-1 in isocratic mode; room temperature and diode array detector at 248 nm. The compounds were eluted at a flow rate of 1.2 ml min . The retention 
time of valsartan was found to be 4.6±0.06 min. Different analytical performance parameters such as specificity, linearity, precision, accuracy, 
limit of detection (LOD), limit of quantification (LOQ), robustness and ruggedness were evaluated according to ICH Q2R1 guidelines. Linearity was 
-1 detected in the concentration range of 10-30 ìg ml  for the drug. The maximum and minimum recovery were found to be 99.95% and 99.57%, 
-1 -1 respectively. LOD and LOQ for valsartan were 0.17ìg ml  and 0.56ìg ml , respectively. Peak purity of the drug was 0.999.  The method developed 
so far was free from interferences due to excipients present in the formulation. Thus, this analytical method was found suitable for routine quality 
control analysis.
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AT -receptor antagonists or sartans, are a group of pharmaceuticals  1
that  modulate  the  renin-angiotensin-aldosterone  system,  with 
particularly high affinity for the type I angiotensin receptor (AT ). By  1
blocking the action of angiotensin, valsartan dilates blood vessels and 
2 reduces blood pressure.  It is an angiotensin receptor blockers that 
selectively inhibits the binding of angiotensin- II to AT , which is found  1
in many tissues such as vascular smooth muscles and the adrenal 
glands. This effectively inhibits the AT -mediated vasoconstrictive and  1
aldosterone-secreting  effects  of  angiotensin-II  and  results  in  a 
decrease  in  vascular  resistance  and  blood  pressure.  Valsartan  is 
selective for AT  and has virtually no affinity for AT . Inhibition of  1 2
aldosterone secretion may inhibit sodium and water reabsorption in the 
kidneys while decreasing potassium excretion. Valsartan is used in the 
treatment of hypertension, to lower blood pressure. Lowering blood 
pressure reduces the risk of fatal and nonfatal cardiovascular events, 
primarily strokes and myocardial infarctions. It is used in the treatment 
of heart failure, and it significantly reduces hospitalization for heart 
failure. It reduces cardiovascular mortality in clinically stable patients 
with left ventricular failure or left ventricular dysfunction following 
3 myocardial infarction.  It has an oral bioavailability of 25% and is 
available in tablet dosage forms. An accurate and precise analytical 
method is important for the estimation of drug content in the dosage 
forms. The objective of this study is to develop a suitable, reliable and 
cost effective method for the estimation of valsartan in oral dosage 
forms. 
2. Materials and Methods
2.1. Materials
Valsartan was received as a gift sample from Alembic Ltd., Vadodara, 
Gujrat, India.  HPLC grade Methanol (Merck), HPLC grade Acetonitrile 
(Merck), HPLC grade water (Merck),   Glacial acetic acid (Fisher 
scientific), HPLC grade and Analytical reagent grade sodium acetate 
anhydrous (Fisher scientific) were used in this study.
2.2. Method development and optimization of chromatographic 
conditions
Shimadzu HPLC system was used for the analysis of valsatran. The 
column used for chromatographic separation was ODS C18 (250mm 
× 4.6mm, 5ìm) (Spincotech Pvt. Ltd., Japan). The mobile phase 
contained a mixture of acetate buffer (pH4.6): acetonitrile: methanol 
(38: 24: 38%, v/v), filtered through 0.45ìm filter paper and deaerated 
in ultra sonic bath sonicator. The analytical wave length was set at 
248 nm. Mobile phase was pumped in isocratic mode (LC-20AD, 
-1 UFLC Shimadzu, Japan) at a flow rate of 1.2ml min . SPD-M20A diode 
array  detector  (Shinadzu)  was  used  in  this  analysis.  Rheodyne 
injector (P/N 7725i) was used for the sample inputs. The separation 
was carried out at room temperature.
2.3. Preparation of standard solution
Accurately, 10 mg of valsartan was weighed and transferred into a 
100 ml volumetric flask. The drug was dissolved in 30 ml of mobile 
phase and the volume was made up to100 ml with mobile phase. Ten 
millilitres of this solution was taken in a 50 ml volumetric flask and the 
volume was adjusted to the mark with mobile phase. Thus, a standard 
strength of 20µg/ml was obtained.
2.4. Preparation of sample solution 
Twenty  Valzaar®  tablets  each  containing  80mg  valsartan  were 
weighed, average weight was calculated and the tablets powdered. 
A quantity of powder equivalent to 80mg valsartan powder was taken 
and dissolved in 50ml of mobile phase and was sonicated for 15min. 
Then, it was shaken and the volume was adjusted up to 100 ml with 
mobile phase. Subsequently, the solution was filtered. From the 
filtrate, 5ml sample was withdrawn and diluted to 50ml with mobile 
phase. Thereafter, 5ml diluted sample was pipetted out and the 
Chemically,  valsatran  is  (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-
tetrazol-5-yl)phenyl] phenyl} methyl) pentanamido] butanoic acid (Fig. 
1 1).
Fig. 1. Chemical structure of valsartan89
volume was adjusted to 20ml with the mobile phase.
3. Results and Discussion
HPLC method was validated for the estimation of valsartan in Valzaar 
80 mg tablets. The composition, pH and the flow rate of the mobile 
phase were optimized. A mobile phase consisting of acetate buffer (pH 
4.6): acetonitrile: methanol (38: 24:38%, v/v), set at a flow rate of 1.2 
-1 ml  min   was  selected  for  use  for  further  studies  after  several 
preliminary  investigatory  chromatographic  runs.  A  typical 
chromatogram obtained from the analysis of drugs using the developed 
method  is  shown  in  Fig.  2.  Under  the  experimental  conditions 
described earlier, all the peaks were well-defined and free from tailing. 
The  effects  of  small  deliberate  changes  in  the  mobile  phase 
composition, pH and flow rate were evaluated as a part of testing for 
method robustness.
-1 Fig. 2. A typical chromatogram of standard valsartan (20ìg ml )
The analytical method was validated with respect to parameters such 
as specificity, linearity, precision, and accuracy, limit of detection 
4-8 (LOD), limit of quantitation (LOQ), and robustness and ruggedness.
The  method  specificity  was  assessed  by  comparing  the 
chromatograms obtained from the drug and the most commonly used 
excipients mixture with those obtained from blank (excipients solution 
in water without drug). The method was specific as none of the 
excipients nor did the blank interfere with the analytes of interest (Table 
1). As evidence, the specific chromatograms are shown in Fig. 3a-c 
and Fig. 3d-e.
Fig. 3d-e. A typical chromatogram of (d) placebo and analyte solution 
and (e) sample solution of valsartan in mobile phase
The  linearity  was  established  by  least  squares  linear  regression 
analysis of the calibration curve. The calibration curves were linear 
-1 over the concentration range of 10-30ìg ml . Peak areas were plotted 
as a function of their respective concentrations and linear regression 
analysis  was  performed  on  the  resultant  curves.  Correlation 
coefficients were found to be 0.999. The results are given in Table 2.
Table 2. Linear regression data for calibration curves
Parameters Valsartan
-1 Linearity Range (µg ml )
Correlation coefficient
Slope
Intercept
10-30
0.999
20888.12
-1.61286
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Table 1. Specificity studies
Drug Sample Area Peak  purity
Valsartan
Blank
Placebo
Standard
Placebo &  Analyte
Sample
None
None
417255
412368
412384
0.00
0.00
1.00
0.99
0.99
Fig. 3a-c. A typical chromatogram of (a) blank solution; (b)  placebo 
solution; (c) standard solution of valsartan in mobile phase   90
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Intra-day precision was investigated by injecting six replicate samples 
of the same batch. Each of the samples was injected on the same day. 
The % RSD obtained for valsartan was found to be 0.61. Inter-day 
precision  was  assessed  by  injecting  the  three  samples  over  six 
consecutive days. The % RSD obtained for valsartan were found to be 
0.89. LOD and LOQ were determined by calibration curve method. LOD 
-1 and LOQ were 0.17 and 0.56ìg ml , respectively. 
Recovery study was carried out by applying the method to a drug 
sample to which a known amount of standard corresponding to 50, 
100 and 150% of label claim was added. At each level of the amount 
added, three determinations were performed. The maximum and 
minimum  recoveries  obtained  were  99.95%  and  99.57%, 
respectively. The results are given in Table 3. 
Table 3. Detailed recovery study protocols and results along with relative standard deviation (%RSD)
% 
Placebo 
added 
(mg)
Amount 
standard 
added (mg)
Amount standard 
added with respect to 
potency(mg)
Amount 
recovered 
(mg)
Recovery % 
RSD
50
100
150
1
2
3
1
2
3
1
2
3
80.15
80.68
80.69
80.60
80.66
80.68
80.65
80.64
80.67
40.02
40.12
40.05
80.13
80.14
79.18
120.21
120.06
120.11 
39.98
40.08
40.01
80.05
80.05
79.10
120.09
119.94
119.99
39.96
39.99
39.99
79.97
79.94
78.96
119.96
119.56
119.47
99.95
99.78
99.95
99.90
99.85
99.82
99.89
99.68
99.57
0.10
0.04
0.16
The robustness of an analytical procedure is a measure of its capacity 
to remain unaffected by small, but deliberate variations in method 
parameters and provides an indication of its reliability during normal 
usage. Robustness of the method was investigated under a variety of 
conditions including changes in composition of buffer in the mobile 
phase, mobile phase buffer pH, and changes in wavelength and flow 
rate. RSD (%) of assay was calculated for each condition. The degree 
of reproducibility of the results obtained as a result of small deliberate 
variations in the method parameters proved that the method was 
robust. The results are cited in Table 4.
Table 4. Robustness studies
Parameters Tailing 
factor
Theoretical 
plates
Retention Time
-1 (min )
Change in assay value 
from mean assay value (%)
Flow rate ( ml )
-1
1.085
1.320
1.12
1.14
3817
3819
5.01
4.20
0.41
0.22
Buffer: Acetonitrile: Methanol 
40:22:38
36:26:38
40:24:36
36:24:40
1.12
1.14
1.15
1.13
3715
3845
3721
3814
4.93
4.37
4.89
4.43
0.23
0.51
0.35
0.26
Buffer pH
4.4
4.8
1.17
1.28
3814
3796
4.57
4.59
0.42
0.63
Wavelength (nm)
245
251
1.26
1.31
3654
3751
4.63
4.66
0.81
0.62
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The ruggedness of the method was assessed by comparison of the 
intra-day  and  inter-day  assay  results  for  valsartan  that  had  been 
performed by two analysts, on two different days. The % RSD values for 
assays performed in the same laboratory by two analysts on two 
different days did not exceed 2, indicating the ruggedness of the 
method. The results are given in Table 5.
Table 5. Ruggedness studies
Parameters  Peak area % RSD, n=6
Analyst-1
Analyst-2
Day-1
Day-2
438521
448512
445561
438923
0.61
0.22
0.31
0.37
The  proposed  RP-HPLC  method  was  applied  to  the  simultaneous 
estimation of valsartan in Valzaar 80mg tablets and drug content in 
each  sample  was  calculated  by  comparison  with  the  appropriate 
standard solution of the drug. No interference due to excipients was 
detected. The assay value was found to be 99.75%.
4. Conclusion
RP-HPLC  method  enabled  the  quantitation  of  valsartan  with  good 
accuracy and precision, whether in laboratory prepared samples or in 
solid pharmaceutical dosage forms. Good recoveries were obtained in 
all  cases.  The  proposed  methods  could  be  applied  efficiently  for 
determination  of  valsartan  in  oral  dosage  form  with  satisfactory 
precision. This method is considered simple, reliable, and selective 
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providing  results  with  satisfactory  accuracy,  and  precision  with 
lower limits of detection and quantification, thus making it more 
specific and sensitive. Moreover, the shorter duration of analysis for 
valsartan makes this analytical method suitable for routine analysis of 
pharmaceutical dosage forms.
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